{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:08:54Z","timestamp":1757628534229,"version":"3.44.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The recurrence of hepatocellular carcinoma (HCC) after liver transplant (LT) occurs in 10% to 15% of cases, but de novo HCC arising in an allograft is a rare occurrence. The aim of this study was to determine the origin of post-LT de novo HCC as either donor or recipient by using molecular analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the LT database (2000-2019), a search was performed for patients who developed de novo HCC and underwent a second LT. Archival formalin-fixed, paraffin-embedded blocks were retrieved. Fragment analysis of 16 polymorphic short tandem repeat (STR) loci was performed on the de novo tumor, background allograft liver, and a recipient control tissue. The origin of the de novo HCC was determined by comparing the informative STR\u2013polymerase chain reaction products from the 3 different specimen sources.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Histologically, the HCC showed well to moderately differentiated morphology. Obliterative portal venopathy (OPV) was seen in all 4 cases, and 2 cases showed nodular regenerative hyperplasia (NRH); cirrhosis was absent in all cases. All HCCs were of donor origin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study shows that in this cohort, all de novo HCCs were of donor origin, and OPV\/NRH was a common concurrent finding. Short tandem repeat analysis is helpful in differentiating whether HCC in the appropriate post-LT clinical setting is of donor origin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf078","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:28:53Z","timestamp":1753273733000},"page":"492-499","source":"Crossref","is-referenced-by-count":0,"title":["Confirmation of the donor origin of de novo hepatocellular carcinoma after liver transplant using microsatellite analysis"],"prefix":"10.1093","volume":"164","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Wisconsin\u2013Madison , Madison, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Houldsworth","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas D","family":"Schiano","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplantation Institute, Mount Sinai Medical Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Isabel","family":"Fiel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025091004262827900_CIT0001","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/ajt.16476","article-title":"De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: a case report","volume":"21","author":"El-domiaty","year":"2021","journal-title":"Am J Transplant."},{"key":"2025091004262827900_CIT0002","doi-asserted-by":"publisher","first-page":"387","DOI":"10.15403\/jgld.2014.1121.243.gpp","article-title":"The Onset of de novo hepatocellular carcinoma after liver transplantation can be both of donor and recipient origin. A case report","volume":"24","author":"Tame","year":"2015","journal-title":"J Gastrointestin Liver Dis."},{"key":"2025091004262827900_CIT0003","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant."},{"key":"2025091004262827900_CIT0004","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/TP.0000000000003998","article-title":"De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH Consensus Conference","volume":"106","author":"Colmenero","year":"2022","journal-title":"Transplantation."},{"key":"2025091004262827900_CIT0005","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2014.11.032","article-title":"De novo hepatocellular carcinoma of liver allograft: a neglected issue","volume":"357","author":"Trevisani","year":"2015","journal-title":"Cancer Lett."},{"key":"2025091004262827900_CIT0006","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ajcp\/aqac026","article-title":"Recurrent liver allograft injury in patients with donor-derived malignancy treated with immunosuppression cessation and retransplantation","volume":"158","author":"Lee","year":"2022","journal-title":"Am J Clin Pathol."},{"key":"2025091004262827900_CIT0007","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s10620-012-2501-0","article-title":"Donor-transmitted malignancy in a liver transplant recipient: a case report and review of literature","volume":"58","author":"Kim","year":"2013","journal-title":"Dig Dis Sci."},{"key":"2025091004262827900_CIT0008","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/liv.14736","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: prognostic and predictive factors of survival in a Latin American cohort","volume":"41","author":"Maccali","year":"2021","journal-title":"Liver Int."},{"key":"2025091004262827900_CIT0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2021.0217","article-title":"The management of post-transplantation recurrence of hepatocellular carcinoma","volume":"28","author":"Rajendran","year":"2022","journal-title":"Clin Mol Hepatol."},{"key":"2025091004262827900_CIT0010","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am J Transplant."},{"key":"2025091004262827900_CIT0011","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4174\/astr.2021.101.1.28","article-title":"Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation","volume":"101","author":"Kim","year":"2021","journal-title":"Ann Surg Treat Res"},{"key":"2025091004262827900_CIT0012","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21037\/tgh.2017.09.06","article-title":"Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression","volume":"2","author":"Lerut","year":"2017","journal-title":"Transl Gastroenterol Hepatol."},{"key":"2025091004262827900_CIT0013","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.transproceed.2005.03.093","article-title":"De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B","volume":"37","author":"Torbenson","year":"2005","journal-title":"Transplant Proc."},{"key":"2025091004262827900_CIT0014","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12885-018-4175-2","article-title":"Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy","volume":"18","author":"Ramadori","year":"2018","journal-title":"BMC Cancer."},{"key":"2025091004262827900_CIT0015","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodriguez-Peralvarez","year":"2013","journal-title":"J Hepatol."},{"key":"2025091004262827900_CIT0016","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1007\/s10620-013-2736-4","article-title":"Obliterative portal venopathy: a clinical and histopathological review","volume":"58","author":"Aggarwal","year":"2013","journal-title":"Dig Dis Sci."},{"key":"2025091004262827900_CIT0017","doi-asserted-by":"publisher","first-page":"876818","DOI":"10.3389\/fsurg.2022.876818","article-title":"Nodular regenerative hyperplasia after liver transplant: it\u2019s all in the presentation","volume":"9","author":"Chen","year":"2022","journal-title":"Front Surg"},{"key":"2025091004262827900_CIT0018","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/lt.21142","article-title":"Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation","volume":"1313","author":"Debarbhavi","year":"2007","journal-title":"Liver Transpl."},{"key":"2025091004262827900_CIT0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diii.2020.10.010","article-title":"Hepatocellular carcinoma in obliterative portal venopathy","volume":"102","author":"Homsi","year":"2021","journal-title":"Diagn Interv Imaging"},{"key":"2025091004262827900_CIT0020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/01.tp.0000230283.84633.4a","article-title":"De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified","volume":"82","author":"Sotirosoulos","year":"2006","journal-title":"Transplantation."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/492\/63830120\/aqaf078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/492\/63830120\/aqaf078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:26:35Z","timestamp":1757492795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/3\/492\/8210959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf078","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,23]]}}}